NASDAQ:MDXH MDxHealth (MDXH) Stock Forecast, Price & News $3.64 +0.05 (+1.39%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$3.54▼$3.7750-Day Range$2.85▼$4.2052-Week Range$2.47▼$9.49Volume140,849 shsAverage Volume234,163 shsMarket Capitalization$59.30 millionP/E RatioN/ADividend YieldN/APrice Target$11.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MDxHealth MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside188.5% Upside$10.50 Price TargetShort InterestHealthy0.51% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.40) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector472nd out of 1,006 stocksMedical Laboratories Industry12th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingMDxHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, MDxHealth has a forecasted upside of 188.5% from its current price of $3.64.Amount of Analyst CoverageMDxHealth has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.51% of the float of MDxHealth has been sold short.Short Interest Ratio / Days to CoverMDxHealth has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MDxHealth has recently decreased by 6.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMDxHealth does not currently pay a dividend.Dividend GrowthMDxHealth does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDXH. Previous Next 2.5 News and Social Media Coverage News SentimentMDxHealth has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MDxHealth this week, compared to 2 articles on an average week.Search InterestOnly 14 people have searched for MDXH on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MDxHealth insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 12.56% of the stock of MDxHealth is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MDxHealth are expected to grow in the coming year, from ($1.40) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MDxHealth is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MDxHealth is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMDxHealth has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MDxHealth (NASDAQ:MDXH) StockMDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Read More Receive MDXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MDxHealth and its competitors with MarketBeat's FREE daily newsletter. Email Address MDXH Stock News HeadlinesMay 23, 2023 | finance.yahoo.comMDxHealth to Present at the 43rd Annual William Blair Growth Stock ConferenceMay 16, 2023 | marketwatch.com2030, Oncology Precision Medicine Market ResearchJune 1, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 16, 2023 | msn.comBTIG Maintains Buy Rating for MDxHealth: Here's What You Need To KnowMay 16, 2023 | americanbankingnews.comBTIG Research Trims MDxHealth (NASDAQ:MDXH) Target Price to $7.00May 16, 2023 | finanznachrichten.demdxhealth: MDxHealth Reports Q1-2023 ResultsMay 16, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on MDxHealth S.A. Sponsored ADR (MDXH)May 16, 2023 | americanbankingnews.comFinancial Survey: MDxHealth (NASDAQ:MDXH) vs. First Choice Healthcare Solutions (OTCMKTS:FCHS)June 1, 2023 | Vantage Point (Ad)We Called (ARWR) In Advance, Which Stocks Are Next?Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE. May 15, 2023 | finance.yahoo.comMDxHealth SA Sponsored ADR (MDXH) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2023 | finance.yahoo.comMDxHealth Reports Q1-2023 ResultsMay 14, 2023 | markets.businessinsider.comMDxHealth earnings preview: what Wall Street is expectingMay 12, 2023 | marketwatch.comGlobally Liquid Biopsy Products Market Growth Rate 2023May 12, 2023 | msn.comMDxHealth (EBR:MDXH) Price Target Decreased by 85.83% to 1.26May 3, 2023 | americanbankingnews.comHead to Head Analysis: HH&L Acquisition (NYSE:HHLA) and MDxHealth (NASDAQ:MDXH)May 1, 2023 | finance.yahoo.comMDxHealth to Present First Quarter 2023 Financial Results on May 15April 28, 2023 | marketwatch.comGlobal Liquid Biopsy Market by [2023-2029] with Revenue OutsourcingApril 25, 2023 | msn.comShort Volatility Alert: MdxhealthApril 24, 2023 | marketwatch.com2023, The Metabolomic Platform Market is Expected to Witness a Substantial Rise in RevenueApril 19, 2023 | finance.yahoo.comFoundational LCD Covers Select mdx for Prostate CancerApril 19, 2023 | finance.yahoo.comEarnings Preview: MDxHealth SA Sponsored ADR (MDXH) Q1 Earnings Expected to DeclineApril 13, 2023 | americanbankingnews.comContrasting MDxHealth (MDXH) and Its CompetitorsApril 11, 2023 | americanbankingnews.comContrasting MDxHealth (MDXH) & Its CompetitorsApril 10, 2023 | americanbankingnews.comHead to Head Analysis: MDxHealth (MDXH) vs. The CompetitionApril 8, 2023 | americanbankingnews.comCritical Analysis: MDxHealth (MDXH) & Its RivalsApril 6, 2023 | americanbankingnews.comMDxHealth (MDXH) & Its Rivals Head to Head SurveyApril 5, 2023 | americanbankingnews.comContrasting MDxHealth (MDXH) and The CompetitionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MDxHealth and its competitors with MarketBeat's FREE daily newsletter. Email Address MDXH Company Calendar Last Earnings3/08/2023Today5/31/2023Next Earnings (Estimated)8/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDXH CUSIPN/A CIK1872529 Webmdxhealth.com Phone324-364-2070FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$18.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+220.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,040,000.00 Net Margins-104.02% Pretax Margin-118.86% Return on Equity-193.40% Return on Assets-42.11% Debt Debt-to-Equity Ratio1.00 Current Ratio3.27 Quick Ratio3.16 Sales & Book Value Annual Sales$37.05 million Price / Sales1.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book1.58Miscellaneous Outstanding Shares16,290,000Free FloatN/AMarket Cap$59.30 million OptionableNot Optionable Beta0.24 Key ExecutivesMr. Michael K. McGarrity (Age 59)CEO & Exec. Director Comp: $502.44kMr. Ron Kalfus (Age 48)Chief Financial Officer Mr. Joseph Sollee (Age 57)Exec. VP of Corp. Devel. & Gen. Counsel Mr. John A. Bellano (Age 53)Chief Commercial Officer Ms. Miriam Reyes (Age 49)Exec. VP of Operations Dr. Wim Van Criekinge (Age 50)Chief Scientific Officer Mr. Paul MarrExec. VP of Sales for North AmericaMore ExecutivesKey CompetitorsExagenNASDAQ:XGNDermTechNASDAQ:DMTKGenetronNASDAQ:GTHAkuminNASDAQ:AKUPersonalisNASDAQ:PSNLView All CompetitorsInsiders & InstitutionsAlyeska Investment Group L.P.Bought 600,000 shares on 5/16/2023Ownership: 3.684%Ally Bridge Group NY LLCBought 500,000 shares on 5/16/2023Ownership: 3.070%Hood River Capital Management LLCBought 578,025 shares on 5/15/2023Ownership: 3.549%Element Capital Management LLCBought 427,744 shares on 5/12/2023Ownership: 2.626%Sei Investments Co.Bought 168,221 shares on 5/12/2023Ownership: 1.033%View All Insider TransactionsView All Institutional Transactions MDXH Stock - Frequently Asked Questions Should I buy or sell MDxHealth stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MDxHealth in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDXH shares. View MDXH analyst ratings or view top-rated stocks. What is MDxHealth's stock price forecast for 2023? 5 equities research analysts have issued 1-year target prices for MDxHealth's shares. Their MDXH share price forecasts range from $7.00 to $18.00. On average, they predict the company's share price to reach $10.50 in the next year. This suggests a possible upside of 188.5% from the stock's current price. View analysts price targets for MDXH or view top-rated stocks among Wall Street analysts. How have MDXH shares performed in 2023? MDxHealth's stock was trading at $6.61 at the beginning of the year. Since then, MDXH stock has decreased by 44.9% and is now trading at $3.64. View the best growth stocks for 2023 here. When is MDxHealth's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023. View our MDXH earnings forecast. How were MDxHealth's earnings last quarter? MDxHealth SA (NASDAQ:MDXH) posted its quarterly earnings results on Wednesday, March, 8th. The company reported ($1.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by $0.35. The company had revenue of $12.89 million for the quarter, compared to analyst estimates of $14.76 million. MDxHealth had a negative trailing twelve-month return on equity of 193.40% and a negative net margin of 104.02%. When did MDxHealth IPO? (MDXH) raised $45 million in an initial public offering on Thursday, November 4th 2021. The company issued 3,750,000 shares at a price of $12.00 per share. What is MDxHealth's stock symbol? MDxHealth trades on the NASDAQ under the ticker symbol "MDXH." Who are MDxHealth's major shareholders? MDxHealth's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alyeska Investment Group L.P. (3.68%), Hood River Capital Management LLC (3.55%), Ally Bridge Group NY LLC (3.07%), Element Capital Management LLC (2.63%), Perkins Capital Management Inc. (2.51%) and Sei Investments Co. (1.03%). View institutional ownership trends. How do I buy shares of MDxHealth? Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MDxHealth's stock price today? One share of MDXH stock can currently be purchased for approximately $3.64. How much money does MDxHealth make? MDxHealth (NASDAQ:MDXH) has a market capitalization of $59.30 million and generates $37.05 million in revenue each year. The company earns $-44,040,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. How can I contact MDxHealth? MDxHealth's mailing address is CAP Business Center, Herstal, Liege 4040. The official website for the company is mdxhealth.com. The company can be reached via phone at 324-364-2070 or via email at ir@mdxhealth.com. This page (NASDAQ:MDXH) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MDxHealth SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.